Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–19.

Article  PubMed  PubMed Central  Google Scholar 

Meynier S, Rieux-Laucat F. After 95 years, it’s time to eRASe JMML. Blood Rev. 2020;43:100652.

Article  PubMed  Google Scholar 

Mayerhofer C, Niemeyer CM, Flotho C. Current treatment of juvenile myelomonocytic leukemia. J Clin Med. 2021;10(14):3084.

Article  PubMed  PubMed Central  Google Scholar 

Elghetany MT, Cavé H, De Vito R, Patnaik MM, Solary E, Khoury JD. Juvenile myelomonocytic leukemia; moving forward. Leukemia. 2023;37(3):720–2.

Article  PubMed  Google Scholar 

Wehbe Z, Ghanjati F, Flotho C. Induced pluripotent stem cells to model juvenile myelomonocytic leukemia: new perspectives for preclinical research. Cells. 2021. https://doi.org/10.3390/cells10092335.

Article  PubMed  PubMed Central  Google Scholar 

Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2009;33(3):355–62.

Article  PubMed  Google Scholar 

Sakashita K, Kato I, Daifu T, Saida S, Hiramatsu H, Nishinaka Y, et al. In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia. Leukemia. 2015;29(3):606–14.

Article  PubMed  Google Scholar 

Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, Akutagawa J, et al. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun. 2017;8(1):2127.

Article  PubMed  PubMed Central  Google Scholar 

Louka E, Povinelli B, Rodriguez-Meira A, Buck G, Wen WX, Wang G, et al. Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia. J Exp Med. 2021. https://doi.org/10.1084/jem.20180853.

Article  PubMed  PubMed Central  Google Scholar 

Altman AJ, Palmer CG, Baehner RL. Juvenile “chronic granulocytic” leukemia: a panmyelopathy with prominent monocytic involvement and circulating monocyte colony-forming cells. Blood. 1974;43(3):341–50.

Article  PubMed  Google Scholar 

Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991;77(5):925–9.

Article  PubMed  Google Scholar 

Bagby GC Jr, Dinarello CA, Neerhout RC, Ridgway D, McCall E. Interleukin 1-dependent paracrine granulopoiesis in chronic granulocytic leukemia of the juvenile type. J Clin Invest. 1988;82(4):1430–6.

Article  PubMed  PubMed Central  Google Scholar 

Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet. 1996;12(2):137–43.

Article  PubMed  Google Scholar 

Iversen PO, Rodwell RL, Pitcher L, Taylor KM, Lopez AF. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21R. Blood. 1996;88(7):2634–9.

Article  PubMed  Google Scholar 

Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood. 2000;95(2):639–45.

Article  PubMed  Google Scholar 

Singh VK, Kumar N, Kalsan M, Saini A, Chandra R. Mechanism of induction: Induced Pluripotent Stem Cells (iPSCs). J Stem Cells. 2015;10(1):43–62.

PubMed  Google Scholar 

Park B, Yoo KH, Kim C. Hematopoietic stem cell expansion and generation: the ways to make a breakthrough. Blood Res. 2015;50(4):194–203.

Article  PubMed  PubMed Central  Google Scholar 

Gandre-Babbe S, Paluru P, Aribeana C, Chou ST, Bresolin S, Lu L, et al. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood. 2013;121(24):4925–9.

Article  PubMed  PubMed Central  Google Scholar 

Tasian SK, Casas JA, Posocco D, Gandre-Babbe S, Gagne AL, Liang G, et al. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. Leukemia. 2019;33(1):181–90.

Article  PubMed  Google Scholar 

Mulero-Navarro S, Sevilla A, Roman AC, Lee DF, D’Souza SL, Pardo S, et al. Myeloid dysregulation in a human induced pluripotent stem cell model of PTPN11-associated juvenile myelomonocytic leukemia. Cell Rep. 2015;13(3):504–15.

Article  PubMed  PubMed Central  Google Scholar 

Pearson S, Guo B, Pierce A, Azadbakht N, Brazzatti JA, Patassini S, et al. Proteomic analysis of an induced pluripotent stem cell model reveals strategies to treat juvenile myelomonocytic leukemia. J Proteome Res. 2020;19(1):194–203.

Article  PubMed  Google Scholar 

Warmuth M, Kim S, Gu XJ, Xia G, Adrián F. Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol. 2007;19(1):55–60.

Article  PubMed  Google Scholar 

Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004;103(6):2325–31.

Article  PubMed  Google Scholar 

Yu WM, Daino H, Chen J, Bunting KD, Qu CK. Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling. J Biol Chem. 2006;281(9):5426–34.

Article  PubMed  Google Scholar 

Mohi MG, Williams IR, Dearolf CR, Chan G, Kutok JL, Cohen S, et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell. 2005;7(2):179–91.

Article  PubMed  Google Scholar 

Zhao Y, He C, Zhang D, Guo Y, Peng Z, Yu L, et al. Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML. Exp Hematol Oncol. 2023;12(1):20.

Article  PubMed  PubMed Central  Google Scholar 

Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA. 2005;102(52):18962–7.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Z, Guiley KZ, Shokat KM. Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S). Nat Chem Biol. 2022;18(11):1177–83.

Article  PubMed  PubMed Central  Google Scholar 

Nonami A, Sattler M, Weisberg E, Liu Q, Zhang J, Patricelli MP, et al. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood. 2015;125(20):3133–43.

Article  PubMed  PubMed Central  Google Scholar 

Qian J, Li Z, Pei K, Li Z, Li C, Yan M, et al. Effects of NRAS mutations on leukemogenesis and targeting of children with acute lymphoblastic leukemia. Front Cell Dev Biol. 2022;10:712484.

Article  PubMed  PubMed Central  Google Scholar 

Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092–100.

Article  PubMed  Google Scholar 

Sato T, Toki T, Kanezaki R, Xu G, Terui K, Kanegane H, et al. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying down syndrome. Br J Haematol. 2008;141(5):681–8.

Article  PubMed  Google Scholar 

Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, et al. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia. 2020;34(2):662–6.

Arti